Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Eloisa Jantús"'
Autor:
Francisco Exposito, Miriam Redrado, Diego Serrano, Silvia Calabuig-Fariñas, Aida Bao-Caamano, Sandra Gallach, Eloisa Jantus-Lewintre, Angel Diaz-Lagares, Aitor Rodriguez-Casanova, Juan Sandoval, Edurne San Jose-Eneriz, Javier Garcia, Esther Redin, Yaiza Senent, Sergio Leon, Ruben Pio, Rafael Lopez, Julen Oyarzabal, Antonio Pineda-Lucena, Xabier Agirre, Luis M. Montuenga, Felipe Prosper, Alfonso Calvo
Publikováno v:
Cell Death and Disease, Vol 15, Iss 11, Pp 1-16 (2024)
Abstract The treatment of non-small cell lung cancer (NSCLC) patients has significantly improved with recent therapeutic strategies; however, many patients still do not benefit from them. As a result, new treatment approaches are urgently needed. In
Externí odkaz:
https://doaj.org/article/6e85bcef9c6c4041a19b62d5fdc24ce3
KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination
Autor:
Rafael Rosell, Eloisa Jantus-Lewintre, Peng Cao, Xueting Cai, Baojuan Xing, Masaoki Ito, Jose Luis Gomez-Vazquez, Mireia Marco-Jordán, Silvia Calabuig-Fariñas, Andrés Felipe Cardona, Jordi Codony-Servat, Jessica Gonzalez, Kevin València-Clua, Andrés Aguilar, Carlos Pedraz-Valdunciel, Zahra Dantes, Anisha Jain, S Chandan, Miguel Angel Molina-Vila, Oscar Arrieta, Macarena Ferrero, Carlos Camps, Maria González-Cao
Publikováno v:
Cell Communication and Signaling, Vol 22, Iss 1, Pp 1-15 (2024)
Abstract Background KRAS-mutant non-small cell lung cancer (NSCLC) shows a relatively low response rate to chemotherapy, immunotherapy and KRAS-G12C selective inhibitors, leading to short median progression-free survival, and overall survival. The ME
Externí odkaz:
https://doaj.org/article/6654162f004044148f38c519b8f50a91
Autor:
Susana Torres‐Martínez, Silvia Calabuig‐Fariñas, Andrea Moreno‐Manuel, Giulia Bertolini, Alejandro Herreros‐Pomares, Eva Escorihuela, Elena Duréndez‐Saéz, Ricardo Guijarro, Ana Blasco, Luca Roz, Carlos Camps, Eloisa Jantus‐Lewintre
Publikováno v:
Molecular Oncology, Vol 18, Iss 1, Pp 190-215 (2024)
Despite the success of therapies in lung cancer, more studies of new biomarkers for patient selection are urgently needed. The present study aims to analyze the role of galectin‐3 (GAL‐3) in the lung tumor microenvironment (TME) using tumorsphere
Externí odkaz:
https://doaj.org/article/e94f49441c4e4aeda21fd85df71bca0e
Autor:
Ana Patiño-García, Elizabeth Guruceaga, Maria Pilar Andueza, Marimar Ocón, Jafait Junior Fodop Sokoudjou, Nicolás de Villalonga Zornoza, Gorka Alkorta-Aranburu, Ibon Tamayo Uria, Alfonso Gurpide, Carlos Camps, Eloísa Jantus-Lewintre, Maria Navamuel-Andueza, Miguel F. Sanmamed, Ignacio Melero, Mohamed Elgendy, Juan Pablo Fusco, Javier J. Zulueta, Juan P. de-Torres, Gorka Bastarrika, Luis Seijo, Ruben Pio, Luis M. Montuenga, Mikel Hernáez, Idoia Ochoa, Jose Luis Perez-Gracia
Publikováno v:
EBioMedicine, Vol 102, Iss , Pp 105048- (2024)
Summary: Background: Tobacco is the main risk factor for developing lung cancer. Yet, while some heavy smokers develop lung cancer at a young age, other heavy smokers never develop it, even at an advanced age, suggesting a remarkable variability in t
Externí odkaz:
https://doaj.org/article/325b5d8d436b42f0be4be23054440e34
Autor:
Irati Macaya, Marta Roman, Connor Welch, Rodrigo Entrialgo-Cadierno, Marina Salmon, Alba Santos, Iker Feliu, Joanna Kovalski, Ines Lopez, Maria Rodriguez-Remirez, Sara Palomino-Echeverria, Shane M. Lonfgren, Macarena Ferrero, Silvia Calabuig, Iziar A. Ludwig, David Lara-Astiaso, Eloisa Jantus-Lewintre, Elizabeth Guruceaga, Shruthi Narayanan, Mariano Ponz-Sarvise, Antonio Pineda-Lucena, Fernando Lecanda, Davide Ruggero, Purvesh Khatri, Enrique Santamaria, Joaquin Fernandez-Irigoyen, Irene Ferrer, Luis Paz-Ares, Matthias Drosten, Mariano Barbacid, Ignacio Gil-Bazo, Silve Vicent
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-19 (2023)
Abstract Drug combinations are key to circumvent resistance mechanisms compromising response to single anti-cancer targeted therapies. The implementation of combinatorial approaches involving MEK1/2 or KRASG12C inhibitors in the context of KRAS-mutat
Externí odkaz:
https://doaj.org/article/e4df0207a07b4df791d9fb4bec0b4c62
Autor:
Rafael Rosell, Anisha Jain, Jordi Codony-Servat, Eloisa Jantus-Lewintre, Blake Morrison, Jordi Barretina Ginesta, María González-Cao
Publikováno v:
Cancer Biology & Medicine, Vol 20, Iss 7, Pp 500-518 (2023)
Lung oncogenesis relies on intracellular cysteine to overcome oxidative stress. Several tumor types, including non-small cell lung cancer (NSCLC), upregulate the system xc- cystine/glutamate antiporter (xCT) through overexpression of the cystine tran
Externí odkaz:
https://doaj.org/article/c75dc006ae7f4f98914e3994f585c6bd
Autor:
Estela Sánchez‐Herrero, Roberto Serna‐Blasco, Vadym Ivanchuk, Rosario García‐Campelo, Manuel Dómine Gómez, José M. Sánchez, Bartomeu Massutí, Noemi Reguart, Carlos Camps, Sandra Sanz‐Moreno, Silvia Calabuig‐Fariñas, Eloísa Jantus‐Lewintre, Magdalena Arnal, Dietmar Fernández‐Orth, Virginia Calvo, Víctor González‐Rumayor, Mariano Provencio, Atocha Romero
Publikováno v:
Molecular Oncology, Vol 15, Iss 9, Pp 2363-2376 (2021)
Despite impressive and durable responses, nonsmall cell lung cancer (NSCLC) patients treated with anaplastic lymphoma kinase (ALK) inhibitors (ALK‐Is) ultimately progress due to development of resistance. Here, we have evaluated the clinical utilit
Externí odkaz:
https://doaj.org/article/f8857d8e937348c0ac60929a958c48fe
Autor:
Atocha Romero, Eloisa Jantus‐Lewintre, Beatriz García‐Peláez, Ana Royuela, Amelia Insa, Patricia Cruz, Ana Collazo, Javier Pérez Altozano, Oscar Juan Vidal, Pilar Diz, Manuel Cobo, Berta Hernández, Sergio Vázquez Estevez, Gretel Benítez, Maria Guirado, Margarita Majem, Reyes Bernabé, Ana Laura Ortega, Ana Blasco, Joaquim Bosch‐Barrera, Jose M. Jurado, Jorge García González, Santiago Viteri, Carlos Garcia Giron, Bartomeu Massutí, Ana Lopez Martín, Alejandro Rodriguez‐Festa, Silvia Calabuig‐Fariñas, Miguel Ángel Molina‐Vila, Mariano Provencio
Publikováno v:
Molecular Oncology, Vol 15, Iss 1, Pp 43-56 (2021)
Several platforms for noninvasive EGFR testing are currently used in the clinical setting with sensitivities ranging from 30% to 100%. Prospective studies evaluating agreement and sources for discordant results remain lacking. Herein, seven methodolo
Externí odkaz:
https://doaj.org/article/fee84be40c92476693b579001138154a
Autor:
Eloisa Jantus-Lewintre, Bartomeu Massutí Sureda, José Luis González Larriba, Delvys Rodríguez-Abreu, Oscar Juan, Ana Blasco, Manuel Dómine, Mariano Provencio Pulla, Javier Garde, Rosa Álvarez, Inmaculada Maestu, Ramón Pérez de Carrión, Ángel Artal, Christian Rolfo, Javier de Castro, Mónica Guillot, Juana Oramas, Ramón de las Peñas, Lioba Ferrera, Natividad Martínez, Òlbia Serra, Rafael Rosell, Carlos Camps
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Finding angiogenic prognostic markers in advanced non-small-cell lung cancer is still an unmet medical need. We explored a set of genetic variants in the VEGF-pathway as potential biomarkers to predict clinical outcomes of patients with non-small-cel
Externí odkaz:
https://doaj.org/article/53c890df8ad048b5aa884049551e96df
Autor:
Eloisa Jantus Lewintre, Cristina Reinoso Martín, Carlos García Ballesteros, David Montaner, Rosa Farrás Rivera, José Ramón Mayans, Javier García-Conde
Publikováno v:
Haematologica, Vol 94, Iss 2 (2009)
Chronic lymphocytic leukemia is an adult-onset leukemia with a heterogeneous clinical behavior. When chronic lymphocytic leukemia cases were divided on the basis of IgVH mutational status, widely differing clinical courses were revealed. Since IgVH s
Externí odkaz:
https://doaj.org/article/e03950ba8272411991c08c2ba64e7633